Share this article
Share this article
GUELPH, ON, and RIO DE JANEIRO, Brazil, April 6, 2021 /PRNewswire/ - PlantForm Corporation, PlantPraxis Biotecnologia and Bio-Manguinhos/Fiocruz (Health Ministry of Brazil) today announced a collaborative research and development agreement to develop a biosimilar pembrolizumab for the Brazilian market.
The original antibody drug, pembrolizumab, is widely used in immunotherapy to treat a variety of cancers including melanoma, lung cancer, head and neck cancer, and stomach cancer. This agreement advances PlantForm s collaborations in Brazil to make affordable, effective cancer drugs available to millions of Brazilians, said Dr. Don Stewart, PlantForm s President and CEO. It also advances PlantForm s global strategy for biosimilar drug development and manufacturing to increase affordability and access to a wide range of life-saving medications.